Literature DB >> 19215301

Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice.

Anna Lord1, Hillevi Englund, Linda Söderberg, Stina Tucker, Fredrik Clausen, Lars Hillered, Marcia Gordon, Dave Morgan, Lars Lannfelt, Frida E Pettersson, Lars N G Nilsson.   

Abstract

Oligomeric assemblies of amyloid-beta (Abeta) are suggested to be central in the pathogenesis of Alzheimer's disease because levels of soluble Abeta correlate much better with the extent of cognitive dysfunctions than do senile plaque counts. Moreover, such Abeta species have been shown to be neurotoxic, to interfere with learned behavior and to inhibit the maintenance of hippocampal long-term potentiation. The tg-ArcSwe model (i.e. transgenic mice with the Arctic and Swedish Alzheimer mutations) expresses elevated levels of Abeta protofibrils in the brain, making tg-ArcSwe a highly suitable model for investigating the pathogenic role of these Abeta assemblies. In the present study, we estimated Abeta protofibril levels in the brain and cerebrospinal fluid of tg-ArcSwe mice, and also assessed their role with respect to cognitive functions. Protofibril levels, specifically measured with a sandwich ELISA, were found to be elevated in young tg-ArcSwe mice compared to several transgenic models lacking the Arctic mutation. In aged tg-ArcSwe mice with considerable plaque deposition, Abeta protofibrils were approximately 50% higher than in younger mice, whereas levels of total Abeta were exponentially increased. Young tg-ArcSwe mice showed deficits in spatial learning, and individual performances in the Morris water maze were correlated inversely with levels of Abeta protofibrils, but not with total Abeta levels. We conclude that Abeta protofibrils accumulate in an age-dependent manner in tg-ArcSwe mice, although to a far lesser extent than total Abeta. Our findings suggest that increased levels of Abeta protofibrils could result in spatial learning impairment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19215301      PMCID: PMC2752010          DOI: 10.1111/j.1742-4658.2008.06836.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  43 in total

1.  beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology.

Authors:  H Y Wang; D H Lee; M R D'Andrea; P A Peterson; R P Shank; A B Reitz
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

2.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.

Authors:  C Nilsberth; A Westlind-Danielsson; C B Eckman; M M Condron; K Axelman; C Forsell; C Stenh; J Luthman; D B Teplow; S G Younkin; J Näslund; L Lannfelt
Journal:  Nat Neurosci       Date:  2001-09       Impact factor: 24.884

3.  Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits.

Authors:  L A Holcomb; M N Gordon; P Jantzen; K Hsiao; K Duff; D Morgan
Journal:  Behav Genet       Date:  1999-05       Impact factor: 2.805

4.  Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice.

Authors:  M N Gordon; D L King; D M Diamond; P T Jantzen; K V Boyett; C E Hope; J M Hatcher; G DiCarlo; W P Gottschall; D Morgan; G W Arendash
Journal:  Neurobiol Aging       Date:  2001 May-Jun       Impact factor: 4.673

5.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

Authors:  D Morgan; D M Diamond; P E Gottschall; K E Ugen; C Dickey; J Hardy; K Duff; P Jantzen; G DiCarlo; D Wilcock; K Connor; J Hatcher; C Hope; M Gordon; G W Arendash
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

6.  A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease.

Authors:  G Chen; K S Chen; J Knox; J Inglis; A Bernard; S J Martin; A Justice; L McConlogue; D Games; S B Freedman; R G Morris
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

7.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

8.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

9.  Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes.

Authors:  G W Arendash; D L King; M N Gordon; D Morgan; J M Hatcher; C E Hope; D M Diamond
Journal:  Brain Res       Date:  2001-02-09       Impact factor: 3.252

10.  A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice.

Authors:  Ola Philipson; Per Hammarström; K Peter R Nilsson; Erik Portelius; Tommie Olofsson; Martin Ingelsson; Bradley T Hyman; Kaj Blennow; Lars Lannfelt; Hannu Kalimo; Lars N G Nilsson
Journal:  Neurobiol Aging       Date:  2008-01-14       Impact factor: 4.673

View more
  33 in total

1.  Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer's disease.

Authors:  Anna Lord; Ola Philipson; Therése Klingstedt; Gunilla Westermark; Per Hammarström; K Peter R Nilsson; Lars N G Nilsson
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

3.  Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice.

Authors:  Davide Tampellini; Estibaliz Capetillo-Zarate; Magali Dumont; Zhenyong Huang; Fangmin Yu; Michael T Lin; Gunnar K Gouras
Journal:  J Neurosci       Date:  2010-10-27       Impact factor: 6.167

4.  Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis.

Authors:  Oliver Wirths; Christian Erck; Henrik Martens; Anja Harmeier; Constanze Geumann; Sadim Jawhar; Sathish Kumar; Gerd Multhaup; Jochen Walter; Martin Ingelsson; Malin Degerman-Gunnarsson; Hannu Kalimo; Inge Huitinga; Lars Lannfelt; Thomas A Bayer
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

5.  Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.

Authors:  Jacqueline Hofrichter; Markus Krohn; Toni Schumacher; Cathleen Lange; Björn Feistel; Bernd Walbroel; Hans-Jochen Heinze; Sara Crockett; Timothy F Sharbel; Jens Pahnke
Journal:  Curr Alzheimer Res       Date:  2013-12       Impact factor: 3.498

6.  β-amyloid oligomers and prion protein: Fatal attraction?

Authors:  Gianluigi Forloni; Claudia Balducci
Journal:  Prion       Date:  2011-01-01       Impact factor: 3.931

7.  Role of Apolipoprotein E in β-Amyloidogenesis: ISOFORM-SPECIFIC EFFECTS ON PROTOFIBRIL TO FIBRIL CONVERSION OF Aβ IN VITRO AND BRAIN Aβ DEPOSITION IN VIVO.

Authors:  Yukiko Hori; Tadafumi Hashimoto; Hidetoshi Nomoto; Bradley T Hyman; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

8.  Synapses, synaptic activity and intraneuronal abeta in Alzheimer's disease.

Authors:  Davide Tampellini; Gunnar K Gouras
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

9.  Alzheimer's disease biomarkers in animal models: closing the translational gap.

Authors:  Jonathan J Sabbagh; Jefferson W Kinney; Jeffrey L Cummings
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

10.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.